Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy

DISEASE CHARACTERISTICS:

At high risk for ovarian cancer and meets criteria for 1 of the following:

Family history of at least 2 ovarian** or breast cancers* among the patient and first- or second-degree relatives in the same lineage

Multiple primary cancers in the same person may fulfill this requirement
Ashkenazi Jewish ethnicity AND 1 first-degree or 2 second-degree relatives with breast* or ovarian** cancer
Ashkenazi Jewish ethnicity AND had prior breast cancer*
BRCA1/BRCA2 mutation probability > 20% by BRCAPRO
Positive for BRCA1 or BRCA2 mutation
First- or second-degree relative with a BRCA1/BRCA2 mutation NOTE: *At least 1 breast cancer must be premenopausal (diagnosed at age 50 or under if menopausal status unknown); ductal carcinoma in situ qualifies as breast cancer

NOTE: **In relatives, only ovarian epithelial cancer, fallopian tube cancer, and primary papillary serous cancer qualifies as ovarian cancer

No prior or concurrent ovarian cancer, including low malignant potential cancers or primary papillary serous carcinoma of the peritoneum

No clinical evidence of ovarian cancer by physical examination, CA 125 evaluation, and pelvic ultrasound

PATIENT CHARACTERISTICS:

Age

19 and over

Performance status

GOG 0-1

Life expectancy

Not specified

Hematopoietic

WBC > 3,000/mm^3
Granulocyte count > 1,500/mm^3
Platelet count > 100,000/mm^3
No hemophilia or other bleeding disorder
No serious anemia

Hepatic

Transaminases normal
Bilirubin normal

Renal

Creatinine clearance > 80 mL/min OR
Creatinine < 2.0 mg/dL

Pulmonary

No emphysema

Other

Not pregnant or nursing
No psychiatric or psychological condition that would preclude giving informed consent
No concurrent untreated malignancy except nonmelanoma skin cancer
No other medical condition that would preclude blood draws (e.g., chronic infectious disease)

PRIOR CONCURRENT THERAPY:

Biologic therapy

Not specified

Chemotherapy

More than 3 months since prior adjuvant chemotherapy

Endocrine therapy

Concurrent adjuvant hormonal therapy (e.g., tamoxifen, leuprolide, or goserelin) allowed

Radiotherapy

More than 3 months since prior adjuvant radiotherapy

Surgery

More than 3 months since prior intraperitoneal surgery (laparoscopy or laparotomy)
No prior oophorectomy

Other

More than 5 years since prior treatment (excluding hormonal therapy) for metastatic malignancy
No concurrent participation in other ovarian cancer early detection clinical trials